3 results
To determine whether treatment with BEZ235 plus best supportive care prolongs PFS compared with placebo plus best supportive care in patients with advanced pancreas NET, after failure of a mTOR inhibitor therapy
Dual Primary Objectives:* To determine if apixaban is noninferior to VKA (INR target range 2.0-3.0) on the combined endpoint of ISTHmajor or clinically relevant non-major bleeding in patients with NVAF who develop ACS or undergo PCI withplanned…
Primary* To compare the efficacy of RO7239361 (BMS-986089) to placebo in ambulatory boys with Duchenne Muscular Dystrophy.Secondary* To compare the efficacy of RO7239361 (BMS-986089) to placebo using the following tests:- 4 stair climb velocity (…